Literature DB >> 27644248

Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma.

Yun Huang1, Yiming Tao1, Kuan Hu1, Feng Lin1, Xinying Li1, Tiecheng Feng1, Zhi-Ming Wang2.   

Abstract

Hypoxia is known to promote hepatocellular carcinoma (HCC) invasion and metastasis and nuclear inhibitor of protein phosphatase 1 (NIPP1) overexpression contributes to the malignant phenotype in HCC. The aim of this study was to investigate the role of NIPP1 in HCC development under hypoxia. We first conducted a study with 106 cases to explore the association of NIPP1 and/or enhancer of zeste homolog 2 (EZH2) expression with poor prognosis in HCC. Then additional 352 independent cases were recruited to validate the results in the first stage. Hypoxia was induced by culturing HCC cells in 1 % O2 or of the treatment with hypoxic agent. The expression levels of NIPP1/EZH2 in both HCC tissues and HCC cell lines were detected by RT-PCR, Western blot, or immunohistochemistry. We also studied the effects of the loss of function of NIPP1 and EZH2 on malignant phenotypes, downstream pathway, and inflammatory factors activities using gene silencing strategy. Overall, we found that NIPP1 and EZH2 were overexpressed in both HCC tissue samples and HCC cell lines. High expression of HIPP1 was associated with poor prognosis and clinicopathological features in patients with advanced HCC. HIPP1 expression positively correlated with the expression of hypoxia marker (carbonic anhydrase IX). Hypoxia induced high expression of NIPP1. NIPP1/EZH2 knockdown in HCC cell lines under hypoxia suppressed the malignant phenotypes, reduced the expression of hypoxia-inducible Factor 1α, downstream molecules of EZH2, and inhibit the activity of inflammatory factors. In conclusion, we found that NIPP1 could be activated by hypoxia and contributed to hypoxia-induced invasive and metastatic potential in HCC.

Entities:  

Keywords:  Enhancer of zeste homolog 2; Hepatocellular carcinoma; Hypoxia; Hypoxia-inducible factor 1α; Nuclear inhibitor of protein phosphatase 1

Mesh:

Substances:

Year:  2016        PMID: 27644248     DOI: 10.1007/s13277-016-5392-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

1.  Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.

Authors:  Jeong-Seok Nam; Yoshinori Ino; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

2.  The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.

Authors:  Fang Zheng; Yi-Ji Liao; Mu-Yan Cai; Yan-Hui Liu; Tian-Hao Liu; Shu-Peng Chen; Xiu-Wu Bian; Xin-Yuan Guan; Marie C Lin; Yi-Xin Zeng; Hsiang-Fu Kung; Dan Xie
Journal:  Gut       Date:  2011-06-14       Impact factor: 23.059

3.  Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension.

Authors:  Jian-Hong Zhong; Yang Ke; Yan-Yan Wang; Le-Qun Li
Journal:  Gut       Date:  2014-09-03       Impact factor: 23.059

Review 4.  The changing pattern of epidemiology in hepatocellular carcinoma.

Authors:  Helena Nordenstedt; Donna L White; Hashem B El-Serag
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

Review 5.  Hypoxia-inducible factors: crosstalk between inflammation and metabolism.

Authors:  Jessica E S Shay; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2012-04-21       Impact factor: 7.727

Review 6.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 8.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

9.  EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.

Authors:  Yibing Fu; Jing Chen; Bo Pang; Chunyan Li; Jing Zhao; Keng Shen
Journal:  Cell Biochem Biophys       Date:  2015-01       Impact factor: 2.194

10.  EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.

Authors:  Bisrat G Debeb; Yun Gong; Rachel L Atkinson; Nour Sneige; Lei Huo; Ana Maria Gonzalez-Angulo; Mien-Chie Hung; Vicente Valero; Naoto T Ueno; Wendy A Woodward
Journal:  J Exp Clin Cancer Res       Date:  2014-07-23
View more
  3 in total

Review 1.  EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers.

Authors:  Marco Papale; Elisabetta Ferretti; Giuseppe Battaglia; Diana Bellavia; Antonello Mai; Marco Tafani
Journal:  Front Pediatr       Date:  2018-11-19       Impact factor: 3.418

Review 2.  Easy or Not-The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity.

Authors:  Jiaqi Huang; Jie Zhang; Zhengyang Guo; Chen Li; Zhen Tan; Junjie Wang; Jianling Yang; Lixiang Xue
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

Review 3.  Coming in the Air: Hypoxia Meets Epigenetics in Pancreatic Cancer.

Authors:  Claudia Geismann; Alexander Arlt
Journal:  Cells       Date:  2020-10-25       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.